H.C. Wainwright analyst Sean Lee lowered the firm’s price target on CytoSorbents (CTSO) to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the “continued drag” on the company’s Germany revenues.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTSO:
- CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances
- CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
- CytoSorbents implemented workforce and cost reduction program
- CTSO Upcoming Earnings Report: What to Expect?
- Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?